Picture loading failed.

Anti-CD276 therapeutic antibody (Pre-made Omburtamab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Omburtamab (formerly burtomab) is a theranostic monoclonal antibody 8H9, conjugated to to 131 iodine, being developed by Y-mAbs Therapeutics, under a license from Memorial Sloan-Kettering Cancer Center, for the diagnosis and treatment of cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-399-1mg 1mg Inquiry
GMP-Bios-ab-399-10mg 10mg Inquiry
GMP-Bios-ab-399-100mg 100mg Inquiry
GMP-Bios-ab-399-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD276 therapeutic antibody (Pre-made Omburtamab biosimilar,Whole mAb Radiolabelled)
INN Name Omburtamab
TargetCD276
FormatWhole mAb Radiolabelled
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI Structure5cma:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesMemorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics
Conditions Approvedna
Conditions ActiveNeuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer
Conditions DiscontinuedSolid tumours
Development Techna